ClinicalTrials.gg
CompletedNCT03888612mCRPCUpdated Apr 1, 2025

Trial of ARV-110 in Patients With Metastatic Castration Resistant Prostate Cancer

A Phase 1/2 interventional study of ARV-110 in Prostate Cancer Metastatic, sponsored by Arvinas Inc.. Completed at 54 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-01.

Sponsored by Arvinas Inc. · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Apr 2024, 2 years 6 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Mar 2025.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
248
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 3,597 studies in Prostatic Neoplasms with a site in United States — 605 open to participants now, 974 under way, 100 of them phase 3. Prostatic Neoplasms · United States.

Enrollment
436th of 3,024
248 · median 48
Started
2019
with 159 others
Phase 1/2
284 of 3,597
63 open now
Registered
2,380th of 3,597
by date

Among the 3,597 studies in Prostatic Neoplasms with a site in United States, this one is the 436th largest by enrollment of the 3,024 interventional ones that give a count, is one of 160 that started in 2019, is one of 284 in phase 1/2, and was the 2,380th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

605 of the 3,597 studies in Prostatic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

600 more — sign in →

All 605 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,597 studies in Prostatic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

Phase 1/2 dose escalation study to assess the safety and tolerability of ARV-110 in men with mCRPC who have progressed on prior approved systemic therapies for their castrate resistant disease (one of which must be enzalutamide or abiraterone).

03

Conditions studied

  • Prostate Cancer Metastatic

Browse trials for

Keywords

  • Metastatic Prostate Cancer
  • Castrate-Resistant
  • Prostate Cancer
  • mCRPC
  • adenocarcinoma of the prostate
  • bavdegalutamide
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Part A:

  • Patients must be male and at least 18 years of age at the time of signing the .
  • Patients must present with histological, pathological, or cytological confirmed diagnosis of advanced or castration resistant adenocarcinoma of the prostate.
  • Patients must have progressed on at least 2 prior approved systemic therapies for CRPC (at least one must be abiraterone or enzalutamide).
  • Patients with progressive mCRPC
  • Patients must have ongoing ADT with a gonadotropin releasing hormone analog or inhibitor, or orchiectomy (surgical or medical castration).

Part B:

  • Patients must be male and at least 18 years of age at the time of signing the informed consent.
  • Patients must present with histological, pathological, or cytological confirmed diagnosis of advanced or metastatic castration resistant adenocarcinoma of the prostate.
  • Patients must have received at least one but no more than two prior second generation anti-androgen agents (e.g., enzalutamide or abiraterone) for CRPC.
  • Patients must have received no more than one prior chemotherapy regimen in each of the following settings: castrate sensitive and castrate resistant prostate cancer.
  • Patients must have ongoing ADT with a gonadotropin releasing hormone analog or inhibitor, or orchiectomy (surgical or medical castration).

Part B - Phase 2 Expansion Cohort Subgroup 4

  • Patient has received only one prior AR second generation therapy (e.g., abiraterone or enzalutamide) either as treatment for CSPC or CRPC and no more than 1 regimen in CRPC setting.
  • No prior chemotherapy

Exclusion criteria

Exclusion Criteria:

Part A:

  • Patients with known symptomatic requiring (above physiologic replacement doses)
  • Major surgery (as defined by the Investigator) within 4 weeks of first dose of study drug.
  • Radiation therapy within 4 weeks of first dose of study drug or prior irradiation to >25% of the bone marrow. Palliative radiation for the alleviation of pain due to bone will be allowed during the study
  • Systemic anti cancer therapy within 2 weeks of first dose of study drug (6 weeks for bicalutamide, mitomycin C, or nitrosoureas and 4 weeks for abiraterone). Patients are ineligible if they received any other type of anti cancer agent (except agents to maintain castrate status) within 2 weeks before first dose of study drug.

Part B:

  • Patients with known symptomatic brain metastases requiring steroids (above physiologic replacement doses)
  • Major surgery (as defined by the Investigator) within 4 weeks of first dose of study drug.
  • Radiation therapy within 4 weeks of first dose of study drug or prior irradiation to >25% of the bone marrow. Palliative radiation for the alleviation of pain due to bone metastasis will be allowed during the study
  • Systemic anti cancer therapy within 2 weeks of first dose of study drug (6 weeks for bicalutamide, mitomycin C, or nitrosoureas and 4 weeks for abiraterone). Patients are ineligible if they received any other type of anti cancer agent (except agents to maintain castrate status) within 2 weeks before first dose of study drug.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
248 participants (actual)

Study arms

  • Experimental
    ARV-110

    Part A: Oral tablet(s), once or twice daily in 28 day cycles Part B: Oral tablet(s), once or twice daily in 28 day cycles

    Drug: ARV-110

Interventions

  • DrugARV-110

    Part A: Daily oral dosages are predetermined by cohort review committee after the initial starting dose cohort after the first 28 days of treatment Part B: Daily oral dosage and schedule at a recommended Phase 2 dose based on data from Part A

06

What researchers measure

Primary outcomes

  1. Part A: Incidence of Dose Limiting Toxicities of ARV-110

    First Cycle Dose limiting toxicities characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), timing, seriousness, and relationship to study drug

    Time frame: 28 Days

  2. Part A: Number of Patients with Adverse Events as a measure of safety and tolerability of ARV-110

    Adverse events as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), timing, seriousness, and relationship to study drug.

    Time frame: 28 Days

  3. Part A: Incidence of laboratory abnormalities as a measure of safety and tolerability of ARV-110

    Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), and timing.

    Time frame: 28 Days

  4. Part B: Measurement of PSA response rate per PCWG3 accessing anti-tumor activity of ARV-110

    PSA response rate per PCWG3.

    Time frame: 12 Weeks

  5. Part B: Measurement of overall RECIST response rate accessing the anti-tumor activity of ARV-110

    Overall RECIST response rate in patients with measurable disease at baseline.

    Time frame: 12 Weeks

  6. Part B: To evaluate the clinical anti-tumor activity of ARV-110 in patients with mCRPC

    To evaluate the clinical anti-tumor activity (PSA response rate per PCWG3, Overall RECIST RR, rPFS, and PFS) of ARV-110 in patients with mCRPC in different subgroups of patients with mCRPC with predefined tumor genomic and molecular profiles or based on prior therapy.

    Time frame: 12 Weeks

Secondary outcomes

  1. Part A: Anti-tumor activity based on the overall PSA response in the entire study population and in the subsets of patient based on the AR mutational status of their tumor.

    The anti-tumor activity of ARV-110 will be assessed by evaluating the overall PSA response per PCWG3.

    Time frame: 12 Weeks

  2. Part A: Anti-tumor activity based on the overall RECIST response in the entire study population and in the subsets of patient based on the AR mutational status of their tumor.

    The anti-tumor activity of ARV-110 will be assessed by evaluating the overall RECIST response rate.

    Time frame: 12 Weeks

  3. Part A: Anti-tumor activity based on the progression free survival in the entire study population and in the subsets of patient based on the AR mutational status of their tumor.

    The anti-tumor activity of ARV-110 will be assessed by evaluating the time to event progression free survival.

    Time frame: 12 Weeks

  4. Part A: Anti-tumor activity based on the duration of response in the entire study population and in the subsets of patient based on the AR mutational status of their tumor.

    The anti-tumor activity of ARV-110 will be assessed by evaluating the duration of response.

    Time frame: 12 Weeks

  5. Part A: Anti-tumor activity based on the time to progression in the entire study population and in the subsets of patient based on the AR mutational status of their tumor.

    The anti-tumor activity of ARV-110 will be assessed by evaluating the time to progression.

    Time frame: 12 Weeks

  6. Part A: Anti-tumor activity based on the overall survival in the entire study population and in the subsets of patient based on the AR mutational status of their tumor.

    The anti-tumor activity of ARV-110 will be assessed by evaluating the overall survival.

    Time frame: 12 Weeks

  7. Part A: Concentration-time curve (AUC) for single and multiple dose of ARV-110

    PK parameters will be assessed when applicable after a single dose and after multiple once and twice daily doses. Assessment of pharmacokinetic parameter area under the concentration-time curve (AUC).

    Time frame: 28 Days

  8. Part A: Maximum concentration (Cmax) for single and multiple dose of ARV-110

    PK parameters will be assessed when applicable after a single dose and after multiple once and twice daily doses. Assessment of pharmacokinetic parameter maximum concentration (Cmax).

    Time frame: 28 Days

  9. Part A: Minimum concentration (Cmin) for single and multiple dose of ARV-110

    PK parameters will be assessed when applicable after a single dose and after multiple once and twice daily doses. Assessment of pharmacokinetic parameter minimum concentration (Cmin).

    Time frame: 28 Days

  10. Part A: Time to maximum concentration (Tmax) for single and multiple dose of ARV-110

    PK parameters will be assessed when applicable after a single dose and after multiple once and twice daily doses. Assessment of pharmacokinetic parameter time to maximum concentration (Tmax)

    Time frame: 28 Days

  11. Part B: Concentration-time curve (AUC) for single and multiple dose of ARV-110

    PK parameters will be assessed when applicable after a single dose and after multiple once and twice daily doses. Assessment of pharmacokinetic parameter area under the concentration-time curve (AUC).

    Time frame: 28 Days

  12. Part B: Maximum concentration (Cmax) for single and multiple dose of ARV-110

    PK parameters will be assessed when applicable after a single dose and after multiple once and twice daily doses. Assessment of pharmacokinetic parameter maximum concentration (Cmax).

    Time frame: 28 Days

  13. Part B: Minimum concentration (Cmin) for single and multiple dose of ARV-110

    PK parameters will be assessed when applicable after a single dose and after multiple once and twice daily doses. Assessment of pharmacokinetic parameter minimum concentration (Cmin).

    Time frame: 28 Days

  14. Part B: Time to maximum concentration (Tmax) for single and multiple dose of ARV-110

    PK parameters will be assessed when applicable after a single dose and after multiple once and twice daily doses. Assessment of pharmacokinetic parameter time to maximum concentration (Tmax)

    Time frame: 28 Days

  15. Part B: Duration of response

    From the date of first confirmed best overall response of CR or PR to the date of first progression per RECIST 1.1 or PCWG3, or death due to any cause without evidence of radiographic progression, whichever occurs first.

    Time frame: 12 Weeks

  16. Part B: Overall survival

    Time interval from the date of first ARV-110 dose to the date of death due to any cause.

    Time frame: 12 Weeks

07

Study locations

54 sites
  • Clinical Trial Site
    Los Angeles, California 90095, United States
  • Clinical Trial Site
    Orange, California 92868, United States
  • Clinical Trial Site
    San Francisco, California 94158, United States
  • Clinical Trial Site
    New Haven, Connecticut 06510, United States
  • Clinical Trial Site
    Altamonte Springs, Florida 32701, United States
  • Clinical Trial Site
    Bonita Springs, Florida 34135, United States
  • Clinical Trial Site
    Bradenton, Florida 34211, United States
  • Clinical Trial Site
    Brandon, Florida 33511, United States
  • Clinical Trial Site
    Cape Coral, Florida 33939, United States
  • Clinical Trial Site
    Clearwater, Florida 33761, United States
  • Clinical Trial Site
    Daytona Beach, Florida 32117, United States
  • Clinical Trial Site
    Fleming Island, Florida 32003, United States
  • Clinical Trial Site
    Fort Myers, Florida 33908, United States
  • Clinical Trial Site
    Gainesville, Florida 32605, United States
  • Clinical Trial Site
    Largo, Florida 33770, United States
  • Clinical Trial Site
    Lecanto, Florida 34461, United States
  • Clinical Trial Site
    Naples, Florida 34102, United States
  • Clinical Trial Site
    New Port Richey, Florida 34655, United States
  • Clinical Trial Site
    Ocala, Florida 34474, United States
  • Clinical Trial Site
    Orange City, Florida 32763, United States
  • Clinical Trial Site
    Orlando, Florida 32806, United States
  • Clinical Trial Site
    Port Charlotte, Florida 33980, United States
  • Clinical Trial Site
    Saint Petersburg, Florida 33705, United States
  • Clinical Trial Site
    Sarasota, Florida 34236, United States
  • Clinical Trial Site
    Spring Hill, Florida 34608, United States
  • Clinical Trial Site
    Stuart, Florida 34994, United States
  • Clinical Trial Site
    Tampa, Florida 33607, United States
  • Clinical Trial Site
    Tavares, Florida 32778, United States
  • Clinical Trial Site
    The Villages, Florida 32159, United States
  • Clinical Trial Site
    Venice, Florida 34292, United States
  • Clinical Trial Site
    Vero Beach, Florida 32960, United States
  • Clinical Trial Site
    Wellington, Florida 33414, United States
  • Clinical Trial Site
    West Palm Beach, Florida 33401, United States
  • Clinical Trial Site
    Winter Park, Florida 32792, United States
  • Clinical Trial Site
    Chicago, Illinois 60611, United States
  • Clinical Trial Site
    New Orleans, Louisiana 70112, United States
  • Clinical Trial Site
    Boston, Massachusetts 02114, United States
  • Clinical Trial Site
    Detroit, Michigan 48201, United States
  • Clinical Trial Site
    Omaha, Nebraska 68130, United States
  • Clinical Trial Site
    Las Vegas, Nevada 89169, United States
  • Clinical Trial Site
    New York, New York 10065, United States
  • Clinical Trial Site
    Portland, Oregon 97239, United States
  • Clinical Trial Site
    Dickson, Tennessee 37055, United States
  • Clinical Trial Site
    Franklin, Tennessee 37067, United States
  • Clinical Trial Site
    Gallatin, Tennessee 37066, United States
  • Clinical Trial Site
    Hendersonville, Tennessee 37075, United States
  • Clinical Trial Site
    Hermitage, Tennessee 37076, United States
  • Clinical Trial Site
    Lebanon, Tennessee 37090, United States
  • Clinical Trial Site
    Murfreesboro, Tennessee 37129, United States
  • Clinical Trial Site
    Nashville, Tennessee 37211, United States
  • Clinical Trial Site
    Shelbyville, Tennessee 37160, United States
  • Clinical Trial Site
    Smyrna, Tennessee 37167, United States
  • Clinical Trial Site
    Salt Lake City, Utah 84112, United States
  • Clinical Trial Site
    Charlottesville, Virginia 22903, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2019 to primary completion in Apr 2024, 61 months.

Of 96 industry-sponsored phase 1/2 interventional studies under Prostatic Neoplasms, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 35. This study's 61 months is above that.

Counting every sponsor, half of 210 studies reached it within 61 months; a quarter within 30 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 21, 2019
First posted
Mar 25, 2019
StartActual
Mar 1, 2019
Primary completionActual
Apr 29, 2024
CompletionActual
Jan 27, 2025
Results delay requested
Mar 28, 2025
Last update
Apr 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03888612
Lead sponsor
Arvinas Inc.
Responsible party
Sponsor
First posted
Mar 25, 2019
Start date
Mar 1, 2019
Primary completion
Apr 29, 2024
Completion
Jan 27, 2025
Last update
Apr 1, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion